FIELD: medicine.
SUBSTANCE: invention represents a combination for treating breast cancer, containing the HSP90 inhibitor and HER2 inhibitor, wherein the HSP90 inhibitor represents ethylamide 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid or its pharmaceutically acceptable salt, as well as a method of treating breast cancer, which involves administering an effective amount of this combination in a patient in need thereof.
EFFECT: combination possesses the higher effectiveness as compared to its individual ingredients.
6 cl, 1 ex, 1 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| KYNURENINE-3-MONOOXYGENASE INHIBITORS | 2009 |
|
RU2523448C2 |
| MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS THROMBIN INHIBITORS | 2011 |
|
RU2639876C2 |
| (AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
| DERIVATIVES OF AMINOINDAZOLS AND THEIR APPLICATION AS KINASES INHIBITORS | 2003 |
|
RU2339624C2 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
| 1,3-DIARYL-SUBSTITUTED UREAS AS KINASE ACTIVITY MODULATORS | 2006 |
|
RU2402544C2 |
